| Illuri Radhika Reddy, MD | |
|
101 Med Tech Pkwy, Suite 305, Johnson City, TN 37604-4007 | |
| (423) 926-6266 | |
| (423) 926-7599 |
| Full Name | Illuri Radhika Reddy |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 101 Med Tech Pkwy, Johnson City, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396777405 | NPI | - | NPPES |
| 3081801 | Medicaid | TN | |
| 64918873 | Medicaid | KY | |
| 1396777405 | Medicaid | VA | |
| 3081807 | Medicaid | TN | |
| 930094971 | Other | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 25510 (Tennessee) | Secondary |
| 207R00000X | Internal Medicine | MD25510 (Tennessee) | Primary |
| Entity Name | T M Carr Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992706097 PECOS PAC ID: 3375504913 Enrollment ID: O20041026000787 |
News Archive
CryoCor, Inc. has announced that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
Obama partisans, you must consider at least two, possibly mixed results -; a politically risky legal battle on the individual mandate in the middle of a presidential campaign, and added insurance that Obama administration lawyers will see the case through its final appeal.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
› Verified 2 days ago
| Entity Name | Appalachian Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689985863 PECOS PAC ID: 6901099639 Enrollment ID: O20101026000515 |
News Archive
CryoCor, Inc. has announced that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
Obama partisans, you must consider at least two, possibly mixed results -; a politically risky legal battle on the individual mandate in the middle of a presidential campaign, and added insurance that Obama administration lawyers will see the case through its final appeal.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
› Verified 2 days ago
| Entity Name | Carr, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548677610 PECOS PAC ID: 1850512153 Enrollment ID: O20141030001974 |
News Archive
CryoCor, Inc. has announced that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
Obama partisans, you must consider at least two, possibly mixed results -; a politically risky legal battle on the individual mandate in the middle of a presidential campaign, and added insurance that Obama administration lawyers will see the case through its final appeal.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
› Verified 2 days ago
| Entity Name | Tri-cities Regional Emergency Physicians, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063950046 PECOS PAC ID: 3678859477 Enrollment ID: O20170410002399 |
News Archive
CryoCor, Inc. has announced that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
Obama partisans, you must consider at least two, possibly mixed results -; a politically risky legal battle on the individual mandate in the middle of a presidential campaign, and added insurance that Obama administration lawyers will see the case through its final appeal.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Illuri Radhika Reddy, MD Po Box 5576, Johnson City, TN 37602-5576 Ph: (423) 926-6266 | Illuri Radhika Reddy, MD 101 Med Tech Pkwy, Suite 305, Johnson City, TN 37604-4007 Ph: (423) 926-6266 |
News Archive
CryoCor, Inc. has announced that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.
Obama partisans, you must consider at least two, possibly mixed results -; a politically risky legal battle on the individual mandate in the middle of a presidential campaign, and added insurance that Obama administration lawyers will see the case through its final appeal.
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).
› Verified 2 days ago
Dr. Alan Cox, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2603 Avondale Dr, Johnson City, TN 37604 Phone: 423-767-8268 | |
Dr. Sheeba Anand, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 N State Of Franklin, Johnson City, TN 37614 Phone: 423-439-6283 | |
Dr. Charles Famoyin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 302 Wesley St, Suite 3, Johnson City, TN 37601 Phone: 423-282-0561 Fax: 423-268-2674 | |
Robert Taylor Means Jr., MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 N State Of Franklin Rd, 2nd Floor, Johnson City, TN 37604 Phone: 423-439-7280 Fax: 423-439-7314 | |
Dr. Tariq Ziad Haddadin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 N State Of Franklin Rd Ste 2, Johnson City, TN 37604 Phone: 423-926-4468 Fax: 423-928-4838 | |
Dr. E Paul Getaz, MD, PHD, MFA, MBA Internal Medicine Medicare: Medicare Enrolled Practice Location: 5 Saint Annes Ct, Johnson City, TN 37604 Phone: 423-946-0708 | |
Timothy O Mcbride, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 E Main St, Johnson City, TN 37601 Phone: 423-929-2584 Fax: 423-722-2060 |